AE-941, a multifunctional antiangiogenic compound: Trials in renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 12, Issue 8, 2003, Pages 1403-1411

  Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Renal cancer; Therapy

Indexed keywords

AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GEMCITABINE; INTERLEUKIN 2; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEOVOSTAT; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; CANCER INHIBITION; CANCER SURVIVAL; CHROMOSOME 3P; CHROMOSOME ABERRATION; CLEAR CELL CARCINOMA; CLINICAL OBSERVATION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; HYPOGLYCEMIA; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; METASTASIS INHIBITION; METHYLATION; MODULATION; MYALGIA; NAUSEA; NONHUMAN; RECEPTOR BINDING; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE EXTRACTS;

EID: 0043136374     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.8.1403     Document Type: Review

References (66)

1. LINEHAN WM, ZBAR B, BATES SE, ZELEFSKY MJ, YANG JC: Cancer of the kidney and ureter. In: Cancer: Principles & Practice of Oncology (Huntingt). S Freeman, S Rhyner, A Snyder, S Harris, TA Scaramuzzo (Eds), Lippincott, Williams & Wilkins, Philadelphia, PA, USA (2001) 1362-1396.
2. MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335:865-875.
3. MOTZER RJ, BACIK J, MARIANIT, RUSSO P, MAZUMDAR M, REUTER V: Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J. Clin. Oncol. (2002) 20:2376-2381.
4. COPPIN C, PROZSOLT F, KUMPF J, COLDMAN A, WILT T: Immunotherapy for advanced renal cell cancer (Cochrane Review). The Cochrane Library, Oxford (2002) 2:1-37 (Update Software).
5. DELAHUNT B, VELICKOVIC M, GREBE SK: Evolving classification of renal cell neoplasia. Expert Rev. Anti-Cancer Ther. (2001) 1:576-584.
6. CENTERS FOR DISEASE CONTROL AND PREVENTION: United States cancer statistics: 1999 incidence. (2002) 1-292.
7. STORKEL S, EBLE JN, ADLAKHA K et al.: Classification of renal cell carcinoma: Workgroup No. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 80:987-989.
8. MOTZER RJ, BACIK J, MARIANI T, RUSSO P, MAZUMDAR M, REUTER V: Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J. Clin. Oncol. (2002) 20:2376-2381.
9. DUENSING S, GROSSE J, ATZPODIEN J: Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anti-Cancer Res. (1995) 15:2331-2334.
10. FUJIMOTO K, ICHIMORO Y, YAMAGUCHI H et al.: Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn. J. Cancer Res. (1995) 86:182-186.
11. DOSQUET C, COUDERT M-C, LEPAGE E et al.: Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma. Clin. Cancer Res. (1997) 3:2451-2458.
12. KAELIN WG: Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer (2002) 2:573-682.
13. GALBAN S, FAN J, MARTINDALE JL et al.: von Hippel-Lindau protein-mediated repression of tumor necrosis factor α translation revealed through use of cDNA arrays. Mol. Cell. Biol. (2003) 23:2316-2328.
14. IVAN M, KAELIN WG: The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. (2001) 11:27-34.
15. FORSYTHE JA, JIANG BH, IYER NV et al.: Activation of vascular endothelial growth Factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. (1996) 16:4604-4613.
16. SEMENZA GL, WANG GL: A nuclear factor induced hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. (1992) 12:5447-5454.
17. FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al.: Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. (2001) 345:1655-1659.
18. YAGODA A, ABI-RACHED B, PETRYLAK D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. (1995) 22:42-60.
19. PEREZ-ZINCER F, OLENCKI T, BUDD GT, PEEREBOOM D, ELSON P, BUKOWSKI RM: A Phase I trial of weekly gemcitabine and subcutaneous interferon α in patients with refractory renal cell carcinoma. Investig. New Drugs (2002) 20(2):305-310.
20. OLIVER RTD, MEHTA A, BARNETT MJ: A Phase II study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol. Biother. (1988) 11:14-20.
21. FAIRLAMB DJ: Spontaneous regression of metastases of renal cancer. Cancer (1981) 47:2102-2106.
22. EIHILALI M, GLEAVE M, FRADET Y et al.: Interferon γ-1b compared with placebo in metastatic renal cell carcinoma. N. Engl. J. Med. (1998) 338:1265.
23. FINKE JH, TUBBS R. CONNELLY B, PONTES E, MONTIE J: Tumor-infiltrating lymphocytes in patients with renal cell carcinoma. Ann. NY Acad. Sci. (1998) 532:387-394.
24. FINKE JH, RAYMAN P, HART L et al.: Characterization of tumor-infiltrating lynmphocyte subsets from human renal A carcinoma: specific reactivity defined by cytotoxicity, interferon-γ secretion, and proliferation. J. Immunther. Emphasis Tumor Immunol. (1994) 15:91-104.
25. NEUMANN E, ENGELBERG A, DECKER J. et al.: Heterogenous expression of the tumor-associated antigens RAGE-1, PRAME and glyooprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. (1998) 58:4090-4095.
26. TATSUMI T, KIERSTEAD LS, RANIERI E et al.: Disease-associated bias in T helper Type 1 (Th1)/Th2 CD4+ T cell responses against mage-6 in HLA-DR+ patients with renal cell carcinoma or melanoma. J. Exp. Med. (2002) 196:619-628.
27. BUKOWSKI RM: Natural history and therapy of metastatic renal cell carcinoma: role of interleukin-2. Cancer (1997) 80:1198-1220.
28. FYFE G, FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, LOUIE AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin-2 therapy. J. Clin. Oncol. (1995) 13:688-696.
29. DORR RT: Interferon-α in malignant and viral diseases: a review. Drugs (1993) 45:177-211.
30. PYRHÖNEN S, SALMINEN E, RUUTU M et al.: Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. (1999) 17:2859-2867.
31. MEDICAL RESEARCH COUNCIL RENAL CANCER COLLABORATORS: Interferon-α and survival in metastatic renal cell carcinoma: early results of randomized trial. Lancet (1999) 353:14-17.
32. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364.
33. GINGRAS D, BATIST G, BELIVEAU R: AE-941 (Neovastat): A novel multifunctional antiangiogenic compound. Expert Rev. AntiCancer Ther. (2001) 1:341-347.
34. EISENSTEIN R, KUETTNER KE, NEOPOLITAN C, SOBLE LW, SORGENTE N: The resistance of certain tissues to invasion. Am. J. Pathol. (1975) 81:337-348.
35. BREM H, FOLKMAN J: Inhibition of tumor angiogenesis mediated by cartilage. J. Exp. Med. (1975) 141:427-439.
36. CASTRONOVO V, DIMITRIODOU V, SAVARD P, RIVIERE M, DUPONT E: Cartilage as a source of natural inhibitors of angiogenesis. In: Antiargiogenic Agents in Cancer Therapy BA Teicher (Ed.), Humana Press, Inc., Totowa, NJ, USA (2000):175-183.
37. LEE A, LANGER R: Shark cartilage contains inhibitors of tumor angiogenesis. Science (1983) 221:1185-1187.
38. HALLAMAN R, FEINBERG RN, LATKER CH, SASSE J, RISAU W: Regression of blood vessels precedes cartilage differentiation during chick limb development. Differentiation (1987) 34:98-105.
39. LATKER CH, FEINBERG RN, BEEBE DC: Localized vascular regression during limb morphogenesis in the chicken embryo: II. Morphological changes in the vasculature. Anat. Rec. (1986) 214:410-417.
40. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumoriogenesis. Cell (1996) 86:353-364.
41. GELB DE, ROSIER RN, PUZAS JE: The production of TGF-β by chick growth-plate chondrocytes in short term monolayer culture. Endocrinology. (1990) 127:1941-1947.
42. HIRAKI Y, KATO Y, INOUE H, SUZUKI F: Stimulation of DNA synthesis in quiescent rabbit chondrocytes in culture by limited exposure to somatomedin-like growth factors. Eur. J. Biochem. (1986) 158:333-337.
43. BROWN RA, TAYLOR C, MCLAUGHLIN B, MCFARLAND CD, WEISS JB, ALI SY: Epiphyseal growth plate cartilage and chondrocytes in mineralising cultures produce a low molecular mass angiogenic procollagenase activator. Bone Miner. (1987) 3:143-158.
44. MOSES MA, SUDHALTER J, LANGER R: Identification of an inhibitor of neovascularization from cartilage. Science (1990) 248:1408-1410.
45. MOSES MA. SUDHALTER J, LANGER R: Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J. Cell. Biol. (1992) 119:475-482.
46. JOHNSON MD, KIM HR, CHESLER C, TSAO-WU G, BOUCK N, POLVERINI PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell. Physiol. (1994) 160:194-202.
47. MURPHY AN, UNSWORTH EJ, STELER-STEVENSON WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol. (1993) 157:351-358.
48. OLKAWA T, ASHINO-FUSE H, SHIMAMURA M, KOIDE U, IWAGUCHI T. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and enbryonic angiogenesis. Cancer Lett. (1990) 51:181-186.
49. SHEU JR, FU CC, TSAI ML, CHUNG WJ: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on antiangiogenesis and anti-tumor activities. Anti-Cancer Res. (1998) 18:4435-4442.
50. LIANG JH, WONG K: The characterization of angiogenesis inhibitors hom shark cartilage. In: Angiogenesis: from sbe Molecular to Integrative Pharmacology. K Maragouchakis (Ed.), Kleuver Academic Press/Plenium Publishers, New York, NY, USA (2000):209-223.
51. DUPONT E, FALARDEAU P, MORISA SA et al.: Antiangiogenic and antimetastatic properties of Neovostat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastais (2002) 19:145-153.
52. GINGRAS D, MOUSSEAU N, GAUMONT-LECLERC MF, BELIEVEAU R: AE-941 (Neovastat) induces endothelial cell apoptosis through activation of caspase-3 activity. Proc. Am. Assoc. Cancer Res. (2001) 42:469.
53. BERGER F, JOURDES P, BENABID AL: AE-941 (Neovastat) induces the expression of angiostatin in experimental glioma. Proc. Am Soc. Clin. Oncol. (2001) 20:100a.
54. WEBER MH, LEE J, ORR : The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int. J. Oncol. (2002) 20:299-303.
55. BERGER F. JOURDE P, BENABID AL: AE-941 (Neovastat) shows a beneficial effect in experimental glioma and is associated with a high angiostatin level in treated tumors. Proc. Am. Assoc. Cancer Res. (2001) 42:724a (Abstract).
56. STETLER-STEVENSON WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. (1999) 103:1237-1241.
57. STETLER-STEVENSON WG: Dynamics of matrix turnover during pathological remodeling of the extracellular matrix. Am. J. Pathol. (1996) 148:1345-1350.
58. STRONGIN AY. MARMER BL, GRANT GA, GOLDBERG GI: Plasma membrane-dependent activation of the 72-kDa Type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. (1993) 268:14033-14039.
59. GINGRAS D, RENAUD A, MOSSEAU N, BEAULIEU E, KACHRA Z, BELIVEAU R: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anti-Cancer Res. (2001) 21:145-155.
60. THOMAS KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. (1996) 271:603-606.
61. WALTENBERGER J, CLAESSONWELSH L, SIEGBAHN A. SHIBUYA M, HEIDIN CH: Different signal transduction properties of KDR and FltI, two receptors for vascular endothelial growth factor. J. Biol. Chem. (1994) 269:26988-26995.
62. BELIVEAU R, GINGRAS D, KRIEGER EA et al.: The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor - mediated biological effects. Clin. Cancer Res. (2002) 8:1242-1250.
63. BELIVEAU R, SIROSIS P, TRANQUI L et al.: Antiangiogenic agent AE-041 induces in vivo and in vitro inhibition of VEGF. Proc. Am. Assoc. Cancer (2000) 41:568 (Abstract).
64. BATIST G, PATENAUDE F, CHAMPAGNE P et al.: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a Phase II trial with two dose levels. Ann. Oncol. (2002) 13:1259-1263.
65. LATREILLE J, BATIST G, LABERGE F et al.: Phase I/II trial of the safety and efficacy of AE-941 (Neovostat®) in the treatment of non-small cell lung cancer. Clin. Lung Cancer (2003) 4:231-236.
66. YANG JC, HAWORTH L, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEFG antibody) demonstrating a prolongation in time to progressin in patients with metastatic renal cancer. Proc. Am. Assoc. Clin. Oncol. (2002) 21:5a (Abstract).